ENGAGE注册研究:八旬及以上患者EVAR中期结局分析
基于ENGAGE前瞻性单臂注册研究1263例EVAR患者,比较≥80岁(290例)与<80岁(973例)患者的中期结局。八旬患者30天死亡率1.4%对1.2%(p=0.85)、主要不良事件5.2%对3.6%(p=0.23),5年免于二次腔内手术率88.5%对83.2%(p=0.07)。结论认为高龄患者EVAR安全可行,中期动脉瘤相关死亡与年轻患者无统计学差异。
要点
- 八旬患者30天死亡率与主要不良事件率与年轻组无统计学差异。
- 年龄≥80岁、肺部疾病、大动脉瘤直径和肾功能不全是全因死亡独立相关因素。
- 5年免于二次腔内手术率两组无统计学差异(88.5%对83.2%,p=0.07)。
核心结论
- EVAR可在≥80岁患者中安全实施,中期动脉瘤相关死亡与年轻患者无统计学差异。
研究设计与样本
- ENGAGE为前瞻性、观察性、单臂、全球上市后注册研究,共纳入1263例连续EVAR患者。
- 按年龄分为≥80岁组290例(22.9%)和<80岁组973例(77.1%)。
主要发现
- 30天死亡率≥80岁组1.4%(4/290)对<80岁组1.2%(12/973),p=0.85。
- 主要不良事件率≥80岁组5.2%(15/290)对<80岁组3.6%(35/973),p=0.23。
- 多变量分析显示年龄≥80岁、肺部疾病、大动脉瘤直径和肾功能不全是全因死亡的显著相关因素,动脉瘤直径是唯一与动脉瘤相关死亡增加相关的参数。
- 5年免于二次腔内手术率≥80岁组88.5%对<80岁组83.2%,p=0.07,差异未达统计学显著。
临床怎么用
- 对于≥80岁腹主动脉瘤患者,EVAR的围手术期死亡率和主要不良事件率与年轻患者相当,可作为治疗选择。
- 术前应评估肺部疾病、动脉瘤直径和肾功能,这些因素与全因死亡风险独立相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess periprocedural results and secondary endovascular procedure outcomes over 5 years in patients aged ≥80 vs <80 years undergoing endovascular aneurysm repair (EVAR). MATERIALS AND METHODS: Data from the Endurant Stent Graft Natural Selection Global post-market registry (ENGAGE) were used for the analyses. A total of 1263 consecutive patients were enrolled in the prospective, observational, single-arm registry and divided into 2 groups according to age: ≥80 years (290, 22.9%) and <80 years (973, 77.1%). Baseline patient characteristics, risk scores according to the Society for Vascular Surgery (SVS) reporting standards, American Society of Anesthesiologists (ASA) classification, quality of life assessments [EuroQol 5 (EQ5D) index], and treatment outcomes, including all-cause mortality, aneurysm-related mortality, major adverse events, secondary endovascular procedures, and endoleaks were compared between groups. RESULTS: Octogenarians were classified into the highest category of the SVS risk stratification system; however, this did not result in a significant difference in the 30-day mortality [1.4% (4/290) vs 1.2% (12/973) for controls; p=0.85] or major adverse event rates [5.2% (15/290) vs 3.6% (35/973), p=0.23]. Multivariable analysis confirmed that age ≥80 years, pulmonary disease, large aneurysm diameter, and renal insufficiency were significantly associated with all-cause mortality, whereas diameter was the only parameter associated with increased aneurysm-related mortality. The differences in freedom from secondary endovascular procedures over 5 years between octogenarians and controls did not reach statistical significance (88.5% vs 83.2%, p=0.07). CONCLUSION: EVAR can be performed in individuals aged ≥80 years with no statistically significant difference in midterm aneurysm-related deaths compared with younger patients. The findings in this elderly patient cohort show that EVAR can be safely performed with acceptable morbidity rates in octogenarians.
引用
- Mwipatayi BP, Oshin OA, Faraj J, et al. Analysis of Midterm Outcomes of Endovascular Aneurysm Repair in Octogenarians From the ENGAGE Registry. J Endovasc Ther. 2020. PMID: 32436808. doi:10.1177/1526602820923827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。